HomeCompareAMGN vs LMT

AMGN vs LMT: Dividend Comparison 2026

AMGN yields 2.77% · LMT yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $136.1K in total portfolio value· pulled ahead in Year 2
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
LMT
LMT
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full LMT calculator →

Portfolio growth — AMGN vs LMT

📍 AMGN pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNLMT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + LMT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
LMT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
LMT
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, AMGN beats the other by $58,517.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + LMT for your $10,000?

AMGN: 50%LMT: 50%
100% LMT50/50100% AMGN
Portfolio after 10yr
$96.1K
Annual income
$35,321.53/yr
Blended yield
36.76%
📊

Analyst Conviction Gap

Where Wall Street is split right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
LMT
Analyst Ratings
20
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$625.18
+1150.4% upside vs current
Range: $517.00 — $695.00
Altman Z
3.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
LMT buys
0
No recent congressional trades found for AMGN or LMT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNLMT
Forward yield2.77%4.00%
Annual dividend / share$9.66$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR48.6%5%
Portfolio after 10y$164.2K$28.0K
Annual income after 10y$69,743.86$899.19
Total dividends collected$133.8K$6.4K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusBuyBuy
Analyst price target$347.73$625.18

Year-by-year: AMGN vs LMT ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrLMT PortfolioLMT Income/yrGap
1$11,111$411.31$11,120$420.00$9.00LMT
2← crossover$12,524$634.70$12,357$458.31+$167.00AMGN
3$14,394$993.52$13,721$499.76+$673.00AMGN
4$16,987$1,585.83$15,227$544.58+$1.8KAMGN
5$20,776$2,599.19$16,885$593.02+$3.9KAMGN
6$26,645$4,414.70$18,713$645.34+$7.9KAMGN
7$36,373$7,863.06$20,724$701.81+$15.6KAMGN
8$53,826$14,907.12$22,938$762.73+$30.9KAMGN
9$88,231$30,636.84$25,372$828.41+$62.9KAMGN
10$164,151$69,743.86$28,047$899.19+$136.1KAMGN

AMGN vs LMT: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

LMTIndustrials

LMT is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in LMT shares.

Full LMT Calculator →
📬

Get this AMGN vs LMT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.